{"version":"1.0","type":"link","title":"Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.","author_name":"Marković F 외","author_url":"https://prs-insight.online/author/Markovi%C4%87%20F","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/97247","thumbnail_width":1200,"thumbnail_height":630}